Prenetics Sees FY26 IM8 Revenue of $180M-$200M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Prenetics sees FY26 IM8 revenue $180M-$200M
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRE
About PRE
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prenetics Shifts Focus Exclusively to IM8, Projecting FY 2026 Revenue of $180-$200 Million
- Strategic Realignment: Prenetics has announced a complete focus on the IM8 brand, projecting FY 2026 revenue between $180 million and $200 million, indicating strong confidence in the consumer health market and a commitment to future growth.
- Bitcoin Investment Cessation: As of December 4, 2025, Prenetics has halted daily Bitcoin purchases and will not pursue future acquisitions, allowing for a concentration of resources on IM8's expansion, thereby enhancing strategic clarity.
- Financial Robustness: The company maintains a strong financial position with over $70 million in cash and cash equivalents, 510 BTC, and zero debt, providing a solid foundation for the rapid expansion of IM8.
- Market Opportunity Capture: IM8 achieved over $100 million in annualized recurring revenue within 11 months of launch, making it the fastest-growing brand in supplement industry history, showcasing Prenetics' significant market potential and competitive advantage in the health sector.
Continue Reading
Presearch Sells Out Inaugural NFT Auction, Exceeding 4 Million Tokens
- Successful Inaugural Auction: Presearch's inaugural Node NFT auction sold out on the first day, with all 142 nodes fetching over 4 million tokens, doubling initial expectations and demonstrating strong market demand for decentralized search networks.
- Community-Driven Model: Each NFT serves not only as a piece of art but also grants holders the right to activate a node, which is expected to enhance network participation and provide rewards to users, further driving the development of Presearch's ecosystem.
- Technical Architecture Upgrade: This auction marks the first phase of the rollout for Presearch 3.0, with a new node orchestration system that will enhance global crawling and indexing capabilities, supporting the retrieval of high-value content and improving user experience.
- Economic Cycle Establishment: By tying node licenses to NFTs, Presearch is testing a new model aimed at enhancing the utility and scarcity of PRE tokens through ongoing auctions, promoting a sustainable economic cycle.
Continue Reading